Status:
UNKNOWN
Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases
Lead Sponsor:
University Hospital, Lille
Collaborating Sponsors:
FAI²R (Auto-immune and auto-inflammatory rare diseases French network)
Conditions:
Sars-CoV2
Chronic Inflammatory Rheumatism
Eligibility:
All Genders
Brief Summary
Since December 2019, an international outbreak of respiratory illnesses caused by SARS-CoV-2 called covid-19 has become a global challenge. In France, while the first cases were reported in January, m...
Eligibility Criteria
Inclusion
- All patients, children and adults
- Patients with known chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases with proven/suspected SARS-Cov-2 infection (COVID-19) (by biological data (serological or positive Cov-2 PCR) or CT scan images or clinical observations consistent with covid-19)
Exclusion
- patients opposed to the use of their data
- patients under guardianship, protected persons
Key Trial Info
Start Date :
April 18 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
13770 Patients enrolled
Trial Details
Trial ID
NCT04353609
Start Date
April 18 2020
End Date
December 1 2020
Last Update
April 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Huriez
Lille, France, 59037